Abattis Bioceuticals Corp.
ATTBFOTCHealthcare● Active
$0.00
+$0.00(+2900.00%)
Market Cap$14334
P/E Ratio—
52W High$0.0001
52W Low$0.000001
Abattis Bioceuticals Corp. (ATTBF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ATTBF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2019-09 | 2018-09 | 2017-09 | 2016-09 | 2015-09 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.36M | $0.01M | $0.00M | $0.00M | $0.09M |
| Cost of Revenue | $0.12M | $0.00M | $0.00M | $0.00M | $0.03M |
| Gross Profit | $0.24M | $0.01M | $0.00M | $0.00M | $0.06M |
| Gross Margin %(computed) | 67.62% | 77.37% | — | — | 68.11% |
| Operating Expenses | |||||
| R&D Expenses | $0.00M | $0.03M | $0.02M | $0.04M | $0.08M |
| G&A Expenses | $2.98M | $12.63M | $6.07M | $2.05M | $2.74M |
| Total Operating Expenses | $4.26M | $15.84M | $6.36M | $2.31M | $3.14M |
| Operating Income | ($3.96M) | ($17.37M) | ($6.36M) | ($2.31M) | ($3.08M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.05M | $4.34M | $0.00M | $0.03M | $0.02M |
| Income Before Tax | ($3.06M) | ($77.65M) | ($7.93M) | ($2.41M) | ($5.99M) |
| Income Tax Expense | $0.00M | $3.16M | ($0.29M) | ($0.04M) | ($0.42M) |
| Net Income | ($3.04M) | ($78.01M) | ($7.63M) | ($2.34M) | ($4.47M) |
| Net Margin %(computed) | -852.40% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.01 | $-0.24 | $-0.05 | $-0.02 | $-0.07 |
| Wtd Avg Shares | 470.49M | 322.64M | 148.67M | 95.00M | 68.82M |
| EBITDA | ($2.90M) | ($17.34M) | ($5.34M) | ($2.13M) | ($3.17M) |
| EBITDA Margin %(computed) | -813.34% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CAD · M
Explore more Abattis Bioceuticals Corp. data
About Abattis Bioceuticals Corp. (ATTBF) Income Statement
Abattis Bioceuticals Corp. (ATTBF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2019, ATTBF reported revenue of $0.00B, gross profit of $0.00B (gross margin 67.62%), and net income of ($0.00B) — a net profit margin of -852.40%.
Frequently asked questions
ATTBF · 4 questionsAbattis Bioceuticals Corp. (ATTBF) reported revenue of $0.00B for 2019, up 4163.2% year-over-year.
ATTBF revenueATTBF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09